ALZN
Alzamend Neuro IncKey Statistics
About Alzamend Neuro Inc
Alzamend Neuro Inc. is a biotechnology firm committed to developing groundbreaking therapies for neurodegenerative diseases, with a primary focus on Alzheimer's disease. Utilizing its proprietary drug development platform and a robust intellectual property portfolio, the company aims to meet significant unmet medical needs within the pharmaceutical sector. Through the integration of advanced technologies and strategic collaborations, Alzamend is advancing its therapeutic candidates through clinical trials, with the objective of enhancing patient quality of life. Given its concentrated efforts on critical health issues, Alzamend is well-positioned to make substantial contributions to the field of neurotherapeutics.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-6.94M |
| Operating Margin | 0.00% |
| Return on Equity | -250.00% |
| Return on Assets | -107.00% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.57 |
| Price-to-Book | 1.97 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -3.13 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $3.80M |
| Float | $3.79M |
| % Insiders | 0.53% |
| % Institutions | 6.46% |
Historical Volatility
Volatility is currently contracting